Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Gene therapy for glioblastoma is effectively created by researchers.

2.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

3.

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

4.

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

5.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot